Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Next Previous
Trial Profile

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ultevursen (Primary)
  • Indications Deaf blind disorders; Retinitis pigmentosa; Usher syndromes
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms STELLAR
  • Sponsors ProQR Therapeutics

    • Most Recent Events

    • 19 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2021 According to a ProQR Therapeutics media release, the company present data of this study at the Analyst Event via webcast.
    • 04 Nov 2021 According to a ProQR Therapeutics media release, in Sep 2021, findings from this study will be presented at the European Society of Retina Specialists (EURETINA) virtual congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top